Purchase Order 75N91023P00629
Award Date 7/17/23
Potential Completion Date 9/1/23
Potential Value $22K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Piscataway, NJ 08854, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- <p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,633.62 on August 22, 2017. The order is for peptide services and carries no set-aside designation. Work is performed in Piscataway, New Jersey. The purchase order is firm fixed price and concludes September 30, 2017.</p>
- <p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,567.96 on August 11, 2017, for peptide services. Work is performed at the awardee's facility in Piscataway, New Jersey. The order is firm fixed price and carries a completion date of September 30, 2017.</p>
- <p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $11,484.18 on August 12, 2019, for sequencing services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price and is scheduled for completion by September 11, 2019.</p>
- <p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for peptide services on August 17, 2017, with a ceiling value of $8,353.96 and an ultimate completion date of September 30, 2017. Work is performed in Piscataway, New Jersey. The order is a firm fixed price purchase order with no set-aside.</p>
- <p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for peptide services valued at $7,701.00 on July 11, 2017. Place of performance is Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of August 9, 2017.</p>
- <p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. for $3,597.96 on August 29, 2017, for peptide services. Work is performed in San Diego, California. The order is firm fixed price with an ultimate completion date of September 30, 2017.</p>
- <p>The National Cancer Institute issued a $5,311.02 delivery order to Genscript USA Inc. on November 3, 2015, for peptide services. Place of performance is Piscataway, New Jersey. The order has a firm fixed price and an ultimate completion date of December 3, 2015.</p>
- <p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $3,964.20 on September 5, 2017, for peptide services. Work is performed in Piscataway, New Jersey. The order carries a firm fixed price structure and ultimate completion date of October 5, 2017.</p>
- <p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $6,230.90 on April 2, 2018, with an ultimate completion date of May 3, 2018. No set-aside category was used. Place of performance is Piscataway, New Jersey. The order carries firm fixed price pricing for biotechnology and molecular biology services, consistent with Genscript's core offerings in gene synthesis, protein production, and antibody development for federal research institutions.</p>
- <p>The National Cancer Institute awarded a purchase order to Genscript USA Inc. valued at $8,786.64 on August 15, 2017, for peptide services. Work is performed in Piscataway, New Jersey. The order is firm fixed price with an ultimate completion date of September 30, 2017. No set-aside category was applied.</p>